Drug Trial Radar · NCT07918001
Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Feb 25, 2026
Primary completion
Feb 28, 2027
Study completion May 10, 2027
Sponsor
- Lead sponsor
- IR INNOVATE RESEARCH PRIVATE LIMITEDIndustry
- Sponsor type
- Industry
- Collaborators
- Glenmark Pharmaceuticals Ltd. India
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The CLEAN ACNE Study is a prospective, observational, Phase IV, open-label, multicenter, single-arm study at 3-5 sites in Vietnam. It will describe the safety, tolerability, and clinical effectiveness of adapalene 0.1%/clindamycin 1% fixed-dose combination gel (Klenzit®-C) as used in routine clinical practice. Participants are Vietnamese patients aged 12 years and older with mild to moderate acne vulgaris. Patients whose treating physician has already prescribed Klenzit®-C as part of routine care will be invited to take part. The decision to prescribe is made independently of the study. About 360 participants will apply the gel once daily, preferably in the evening, for 12 weeks. Study visits take place at baseline and at Weeks 2, 4, 8, and 12. The main focus is safety and tolerability. This includes adverse events and local skin reactions such as redness, dryness, darkening of the skin, peeling, and itching. The study will also observe changes in inflammatory and non-inflammatory acne lesion counts. It will record the proportion of participants who reach treatment success on the Investigator Global Assessment (IGA) at Weeks 4, 8, and 12. An interim safety review will take place at Week 2, once about half of the participants have enrolled.
Conditions
- Acne
Interventions
Klenzit®-C (Adapalene/Clindamycin Phosphate Gel)Drug
Klenzit®-C (Adapalene/Clindamycin Phosphate Gel) Description: Topical gel containing adapalene 1 mg/g and clindamycin 10 mg/g, applied once daily to acne-affected areas of the face after cleansing and drying the skin. It is prescribed as part of routine clinical practice and not assigned by the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs and SAEs, and AEs Leading to DiscontinuationTime frame: From signing of informed consent up to Week 12 (Day 84)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Bach Mai Hospital
Hanoi, Vietnam · Not yet recruiting
Ho Chi Minh City Hospital of Dermatology and Venereology
Hanoi, Vietnam · Recruiting
Le Van Thinh Hospital
Ho Chi Minh City, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.